Middle-ear infection, or otitis media, is the number one reason for pediatric antibiotic prescriptions, but getting oral antibiotics into young children several times a day for seven to 10 days is a daunting task, said researchers led by Boston Children's Hospital in the US.
"Force-feeding antibiotics to a toddler by mouth is like a full-contact martial art," said Daniel Kohane, the study's senior investigator.
Incomplete treatment and frequent recurrence of otitis media (40 per cent of children have four or more episodes) encourage the development of drug-resistant infections.
Since high doses are needed to get enough antibiotic to the ear, side effects like diarrhoea, rashes and oral thrush are common.
"With oral antibiotics, you have to treat the entire body repeatedly just to get to the middle ear," said Rong Yang, a chemical engineer in Kohane's lab.
"With the gel, a pediatrician could administer the entire antibiotic course all at once, and only where it's needed," said Yang.
"Our technology gets things across the eardrum that don't usually get across, in sufficient quantity to be therapeutic," said Kohane.
Previously, the eardrum (also called the tympanic membrane) was an impenetrable barrier, said researchers, including Vishakha Sabharwal of Boston Medical Centre.
The bioengineered gel gets drugs past it with the help of chemical permeation enhancers (CPEs).
The CPEs insert themselves into the membrane, opening up molecular pores that allow the antibiotics to seep through.
When tested in chinchillas (rodents with a hearing range and ear structure similar to those of humans), the gel dispensed high concentrations of the antibiotic ciprofloxin in the middle ear and completely cured ear infections due to Haemophilus influenza in all the 10 animals.
There was no observable toxicity, and no antibiotic was detected in the animals' blood. Yang and Kohane observed a slight hearing loss, similar to that caused by earwax. Giving less of the gel alleviated the problem.
The findings were published in the journal Science Translational Medicine.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
